Champions Oncology (CSBR) Current Deferred Revenue (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Current Deferred Revenue of $8.8 million for Q2 2026, down 42.83% year-over-year from $15.4 million in Q2 2025, and down 11.7% quarter-over-quarter from $10.0 million in Q1 2026.
Champions Oncology (CSBR) Current Deferred Revenue (2011 - 2026) Analysis & Trends
Champions Oncology's Current Deferred Revenue history runs 16 years deep, the most recent figure standing at $8.8 million for Q2 2026.
- In Q2 2026, Current Deferred Revenue fell 42.83% year-over-year to $8.8 million; the TTM figure through Apr 2026 stood at $8.8 million (down 42.83% YoY), while the FY2026 annual figure was $8.8 million, down 42.83% from the prior year.
- Current Deferred Revenue for Q2 2026 stood at $8.8 million, down from $10.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $15.4 million in Q2 2025, with the low at $8.7 million in Q1 2022.
- The 5-year median for Current Deferred Revenue is $11.2 million (2022), against an average of $11.7 million.
- The sharpest annual moves came in 2022 and 2026: Current Deferred Revenue soared 98.87% in 2022, then sank 42.83% in 2026.
- Champions Oncology's Current Deferred Revenue stood at $11.2 million in 2022, then increased by 16.07% to $13.0 million in 2023, then decreased by 21.38% to $10.2 million in 2024, then rose by 20.72% to $12.3 million in 2025, then slipped by 28.45% to $8.8 million in 2026.
- Business Quant data shows CSBR's Current Deferred Revenue at $8.8 million in Q2 2026, $10.0 million in Q1 2026, and $12.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - |
| 10 | Champions Oncology | 72.07 Mn | 72.07 Mn | 7.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 8.83 Mn |
| Jan 31, 2026 | 10.00 Mn |
| Oct 31, 2025 | 12.34 Mn |
| Jul 31, 2025 | 14.43 Mn |
| Apr 30, 2025 | 15.44 Mn |
| Jan 31, 2025 | 10.92 Mn |
| Oct 31, 2024 | 10.22 Mn |
| Jul 31, 2024 | 10.31 Mn |
| Apr 30, 2024 | 12.09 Mn |
| Jan 31, 2024 | 13.33 Mn |
| Oct 31, 2023 | 13.00 Mn |
| Jul 31, 2023 | 11.10 Mn |
| Apr 30, 2023 | 12.78 Mn |
| Jan 31, 2023 | 13.16 Mn |
| Oct 31, 2022 | 11.20 Mn |
| Jul 31, 2022 | 10.90 Mn |
| Apr 30, 2022 | 11.10 Mn |
| Jan 31, 2022 | 8.70 Mn |
| Oct 31, 2021 | 6.13 Mn |
| Jul 31, 2021 | 5.48 Mn |